Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 7/20 | 0.35 |
| ▸ | CNR1 | P21554 | 4/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25145671 | 1.00 | ALOX5AP (0.36) | ALOX5APFEN1GPR119CNR2CNR1 | |
| SCHEMBL25325345 | 0.76 | ABHD6 (0.40) | ALOX5APFEN1GPR119ABHD6FAAH | |
| SCHEMBL25325348 | 0.76 | ABHD6 (0.40) | ALOX5APFEN1GPR119ABHD6FAAH | |
| SCHEMBL25145962 | 0.76 | CNR2 (0.36) | CNR2CNR1 | |
| SCHEMBL31239653 | 0.76 | CNR2 (0.36) | CNR2CNR1 | |
| SCHEMBL30410134 | 0.76 | MGLL (0.43) | ABHD6FAAHMGLL | |
| SCHEMBL25146290 | 0.76 | MGLL (0.43) | ABHD6FAAHMGLL | |
| SCHEMBL29427117 | 0.72 | DDB1 (0.44) | ABHD6FAAHMGLL | |
| SCHEMBL26631392 | 0.72 | DDB1 (0.44) | ABHD6FAAHMGLL | |
| SCHEMBL27246542 | 0.70 | PTGDR2 (0.35) | CNR2CNR1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | MAGI3, MAG, MAGT1 | ALOX5AP 2101/4885FEN1 3485/4885GPR119 4426/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | ALOX5AP 2464/4885FEN1 4564/4885GPR119 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.